Clinical trial · Observational
Shared Care Thyroid Cancer Follow-up Utilizing Thyroid Cancer Assessment Reminder System (TCARS) Study - A Pilot Study.
NCT05510934CI-TRIAL-00079994unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to assess the feasibility of a shared-care model for low-risk differentiated thyroid cancer (DTC) patients, primary care practitioners (PCPs) and the tertiary care center utilizing a digital health-based thyroid cancer assessment reminder system (TCARS) in Medable with an expedited referral to specialists for rapid assessment in case of a concern of recurrence.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Low Risk Differentiated Thyroid Cancer | Thyroid Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Shared-care model | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Shared-care Group
- description
- The Shared-care Group will comprise of patients who are receiving long term follow-up care for their condition by their PCP.
- interventionNames
- Behavioral: Shared-care model
- label
- Control Group
- description
- The Control Group will be made of patients who are receiving long term follow-up care for their condition of low-risk DTC at the Halifax Interdisciplinary Thyroid Oncology Clinic (ITOC).
Primary outcomes (2)
- measure
- Feasibility outcomes
- timeFrame
- after up to 24 months (after the 2nd Follow-up)
- description
- These outcomes will assess the feasibility of the pilot study. These include: * Number (%) of eligible patients who are approached for the study and agree to participate in either group. * Number (%) of eligible patients who are are approached for the study but refuse to participate in either group and reason for refusal. * Number (%) of patients who remain in the shared-care group at study end. * Number of patients who choose to terminate the study in either group and reason for termination. * Number of patients who lost their PCP and returned to specialist care.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Adult (\>18 years old) consenting patients being followed at the Halifax Interdisciplinary Thyroid Oncology Clinic (ITOC) meeting the following criteria: * AJCC stage 1 DTC with no radiological or biochemical evidence of thyroid cancer with undetectable high sensitivity serum thyroglobulin (hsTG \<0.06 mcg/L\*); * Anti-thyroglobulin antibody (anti-TG AB \<20 IU/ml\*); * Thyroid ultrasound scan \[USS\] negative for regional recurrence at least 24 months after most recent treatment; * AJCC stage 2 DTC with no radiological or biochemical evidence of cancer (undetectable hsTG and anti-TG AB and negative thyroid USS) at least 48 months after most recent treatment * Patient is comfortable with using the mobile or Medable application and has access to internet. Exclusion Criteria: Patient does not have a consented PCP.
References
Publications (0)
Data not yet available
No reference posted for this study.